



Aratana Therapeutics: Striving for Three FDA Approvals in 2016

Just a few months ago, in December 2015, Aratana Therapeutics reached a major milestone – their fifth anniversary. At the celebration, the company reminisced about the past and focused on looking forward to 2016, a year of *new beginnings* for the company.

Aratana Therapeutics' business model is to provide first-in-class therapeutic solutions by exploring the intersection of human and animal health. Thus, the company was founded in the heart of the Kansas City Animal Health Corridor in 2010 with the goal to take the best from human medical research and apply the learnings to solve unmet or underserved medical needs for important members of our family – dogs and cats.

On March 20, the Company achieved the first of three anticipated Food and Drug Administration's Center for Veterinary Medicine (CVM) approvals. GALLIPRANT® (grapiprant tablets) received FDA approval for the control of pain and inflammation associated with osteoarthritis in dogs. Galliprant is expected to be available to veterinarians in fall 2016. Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist (PRA) that blocks PGE2-elicited pain and inflammation.

"As the first approved product in the new piprant class, Galliprant offers veterinarians a needed therapeutic option for the millions of dogs treated each year for osteoarthritis," explains Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "Clinical studies have shown Galliprant offers proven efficacy when compared to placebo and is well-tolerated in dogs."

On March 22, Aratana announced submitting an administrative New Animal Drug Application (NADA) with CVM for their second therapeutic, ENTYCE® (capromorelin oral solution), an investigational candidate for appetite stimulation for dogs. The company anticipates FDA approval by May 21 and commercial availability to veterinarians in late-2016 or shortly thereafter. Entyce, a ghrelin agonist, is a new chemical entity and a first-of-its-kind therapeutic to treat inappetence in dogs by mimicking ghrelin, the hunger hormone, to stimulate appetite.

"Our market research indicates that millions of dogs with inappetence are treated off-label with drugs, special diets and homeopathic remedies," stated Ernst Heinen, DVM, PhD, Chief Development Officer of Aratana Therapeutics. "The anticipated FDA approval of Entyce would make it the only therapeutic approved for use by veterinarians to fulfill a serious unmet need for dogs that have stopped eating."

Aratana anticipates filing an administrative NADA for one additional therapeutic later this year.

Important Safety Information

GALLIPRANT® (grapiprant tablets) is for use in dogs only. Do not use in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, or in pregnant or lactating dogs. Adverse reactions in dogs may include mild gastrointestinal effects including, vomiting, diarrhea and decreased

appetite. Should not be used in dogs that have a hypersensitivity to grapiprant. Avoid use with COX-inhibiting NSAIDs or corticosteroids. Please see full the Prescribing Information.